FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

ZELDIS JEROME B
2. Issuer Name and Ticker or Trading Symbol

SOLIGENIX, INC. [ SNGX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

29 EMMONS DRIVE, SUITE B-10
3. Date of Earliest Transaction (MM/DD/YYYY)

9/19/2019
(Street)

PRINCETON, NJ 08540
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  9/19/2019    P    4000  A $0.935  20917  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
ZELDIS JEROME B
29 EMMONS DRIVE, SUITE B-10
PRINCETON, NJ 08540
X



Signatures
/s/ Jerome B. Zeldis 9/23/2019
**Signature of Reporting Person Date


Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Soligenix Charts.
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Soligenix Charts.

Soligenix, Inc. News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
Thursday 25 April 2024 (7 days ago) • PR Newswire (US)
Soligenix Announces Pricing of $4.75 Million Public Offering
Thursday 18 April 2024 (2 weeks ago) • PR Newswire (US)
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Monday 15 April 2024 (2 weeks ago) • PR Newswire (US)
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
Thursday 11 April 2024 (3 weeks ago) • PR Newswire (US)
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
Wednesday 3 April 2024 (4 weeks ago) • PR Newswire (US)
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
Friday 15 March 2024 (2 months ago) • PR Newswire (US)
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
Thursday 8 February 2024 (3 months ago) • PR Newswire (US)
Soligenix to Present at The Microcap Conference
Thursday 25 January 2024 (3 months ago) • PR Newswire (US)
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
Monday 8 January 2024 (4 months ago) • PR Newswire (US)
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
Thursday 4 January 2024 (4 months ago) • PR Newswire (US)
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
Tuesday 2 January 2024 (4 months ago) • PR Newswire (US)
Form 8-K - Current report
Saturday 23 December 2023 (4 months ago) • Edgar (US Regulatory)